NASDAQ:NTRA

Natera Stock Forecast, Price & News

$90.25
-0.34 (-0.38 %)
(As of 05/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$87.50
$93.99
50-Day Range
$90.59
$115.92
52-Week Range
$39.21
$127.19
Volume1.28 million shs
Average Volume870,989 shs
Market Capitalization$7.91 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.66
30 days | 90 days | 365 days | Advanced Chart
Receive NTRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.


Natera logo

About Natera

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTRA
CUSIPN/A
Phone650-249-9090
Employees1,815
Year FoundedN/A

Sales & Book Value

Annual Sales$302.33 million
Book Value$3.59 per share

Profitability

Net Income$-124,830,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap$7.91 billion
Next Earnings Date8/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.71 out of 5 stars

Medical Sector

248th out of 2,045 stocks

Medical Laboratories Industry

5th out of 38 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Natera (NASDAQ:NTRA) Frequently Asked Questions

Is Natera a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Natera stock.
View analyst ratings for Natera
or view top-rated stocks.

What stocks does MarketBeat like better than Natera?

Wall Street analysts have given Natera a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Natera wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Natera's next earnings date?

Natera is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Natera
.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) announced its quarterly earnings results on Thursday, May, 6th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.31. The medical research company had revenue of $152.32 million for the quarter, compared to analyst estimates of $114.42 million. Natera had a negative net margin of 52.11% and a negative trailing twelve-month return on equity of 53.39%. Natera's quarterly revenue was up 62.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.45) earnings per share.
View Natera's earnings history
.

How has Natera's stock price been impacted by COVID-19?

Natera's stock was trading at $31.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NTRA shares have increased by 190.9% and is now trading at $90.25.
View which stocks have been most impacted by COVID-19
.

What guidance has Natera issued on next quarter's earnings?

Natera issued an update on its FY 2021 earnings guidance on Thursday, May, 6th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $550 million-$575 million, compared to the consensus revenue estimate of $514.68 million.

What price target have analysts set for NTRA?

10 equities research analysts have issued 1-year price targets for Natera's stock. Their forecasts range from $36.00 to $150.00. On average, they anticipate Natera's share price to reach $114.70 in the next year. This suggests a possible upside of 27.1% from the stock's current price.
View analysts' price targets for Natera
or view top-rated stocks among Wall Street analysts.

Who are Natera's key executives?

Natera's management team includes the following people:
  • Dr. Matthew Rabinowitz, Co-Founder & Exec. Chairman (Age 48, Pay $497.18k)
  • Mr. Steve Chapman, CEO, Pres & Director (Age 42, Pay $680.92k)
  • Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 48, Pay $297.13k)
  • Mr. Michael Brophy, Chief Financial Officer (Age 41, Pay $521.62k)
  • Mr. Robert A. Schueren, Chief Operating Officer (Age 59, Pay $626.18k)
  • Mr. Eric A. Evans, Chief Scientific Officer
  • Mr. Daniel Rabinowitz L.L.M., LL.M., Sec. & Gen. Counsel
  • Mr. Phil Grinnell, VP of Sales
  • Dr. Ramesh Hariharan, VP of Marketing & Medical Education
  • Paul Greenland, VP of Corp. Marketing

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera CEO Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among Natera's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Natera's key competitors?

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Who are Natera's major shareholders?

Natera's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.34%), Lord Abbett & CO. LLC (1.68%), Jennison Associates LLC (1.30%), Principal Financial Group Inc. (0.84%), Kornitzer Capital Management Inc. KS (0.57%) and Westwood Management Corp IL (0.33%). Company insiders that own Natera stock include Gail Boxer Marcus, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren, Rowan E Chapman, Roy D Baynes, Steven Leonard Chapman and Todd C Cozzens.
View institutional ownership trends for Natera
.

Which institutional investors are selling Natera stock?

NTRA stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, BNP Paribas Arbitrage SA, Kornitzer Capital Management Inc. KS, Russell Investments Group Ltd., New York State Common Retirement Fund, Tygh Capital Management Inc., Calamos Advisors LLC, and Royce & Associates LP. Company insiders that have sold Natera company stock in the last year include Gail Boxer Marcus, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren, Rowan E Chapman, Roy D Baynes, Steven Leonard Chapman, and Todd C Cozzens.
View insider buying and selling activity for Natera
or view top insider-selling stocks.

Which institutional investors are buying Natera stock?

NTRA stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Principal Financial Group Inc., BlackRock Inc., Westwood Management Corp IL, Assenagon Asset Management S.A., Compagnie Lombard Odier SCmA, Eagle Health Investments LP, and Envestnet Asset Management Inc..
View insider buying and selling activity for Natera
or or view top insider-buying stocks.

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $90.25.

How much money does Natera make?

Natera has a market capitalization of $7.91 billion and generates $302.33 million in revenue each year. The medical research company earns $-124,830,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis.

How many employees does Natera have?

Natera employs 1,815 workers across the globe.

What is Natera's official website?

The official website for Natera is www.natera.com.

Where are Natera's headquarters?

Natera is headquartered at 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected]


This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.